Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 3, 2007

Caliper Gains Control over Most of Monogram’s Microfluidics Patent Estate

  • Monogram Biosciences has licensed most of its microfluidics patent portfolio to Caliper Life Sciences on an exclusive basis. The addition of this IP brings Caliper’s patent estate available for licensing under the Caliper Driven licensing program includes over 335 U.S. patents.

    "Microfluidics technology is gaining mainstream market adoption," remarks Kevin Hrusovsky, CEO of Caliper Life Sciences. “It is a next-generation experimentation platform offering data quality, workflow integration, and scalability for critical research and diagnostic applications. By incorporating Monogram's microfluidic patent estate into our own, we are able to expand the overall breadth and versatility of the applications that we can now pursue—either on our own or with partners through our Caliper Driven program."

    The intellectual property (IP) licensed to Caliper originates from ACLARA BioSciences, which merged with Monogram in 2004.

    Under the terms of the license agreement, Monogram retains the right to practice the licensed microfluidics IP for use with its eTag technology.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »